Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)
South Korea · Delayed Price · Currency is KRW 7,990.00
0.00 (0.00%)
At close: Mar 27, 2026
Ahn-Gook Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 306,874 | 271,116 | 233,676 | 205,389 | 163,534 |
Other Revenue | -0 | - | - | -0 | - |
| 306,874 | 271,116 | 233,676 | 205,389 | 163,534 | |
Revenue Growth (YoY) | 13.19% | 16.02% | 13.77% | 25.59% | 14.07% |
Cost of Revenue | 106,572 | 103,219 | 93,105 | 79,109 | 62,516 |
Gross Profit | 200,302 | 167,896 | 140,571 | 126,279 | 101,018 |
Selling, General & Admin | 160,767 | 145,430 | 121,343 | 102,052 | 83,157 |
Research & Development | 26,897 | 13,259 | 12,255 | 12,957 | 17,328 |
Amortization of Goodwill & Intangibles | 236.38 | 262.3 | 266.24 | 544.69 | 539.11 |
Operating Expenses | 190,504 | 161,219 | 135,509 | 116,899 | 102,102 |
Operating Income | 9,798 | 6,678 | 5,061 | 9,381 | -1,084 |
Interest Expense | -2,755 | -3,002 | -142.75 | -160.41 | -116.83 |
Interest & Investment Income | 379.07 | 463.68 | 388.54 | 407.43 | 335.82 |
Earnings From Equity Investments | -579.82 | 1,352 | -1,641 | -1,645 | 2,613 |
Currency Exchange Gain (Loss) | 72.11 | 68.82 | -79.74 | -82.27 | 133.07 |
Other Non Operating Income (Expenses) | -231.1 | 1,453 | -258.15 | 336.26 | -246.68 |
EBT Excluding Unusual Items | 6,684 | 7,013 | 3,328 | 8,237 | 1,634 |
Gain (Loss) on Sale of Investments | 989.18 | 230.47 | 921.68 | -889.55 | 2,033 |
Gain (Loss) on Sale of Assets | 46.41 | 13,216 | 17.13 | 28.25 | 138.65 |
Asset Writedown | -2.75 | -219.98 | - | - | - |
Pretax Income | 7,717 | 20,239 | 4,267 | 7,375 | 3,805 |
Income Tax Expense | 397.18 | 3,896 | 3,269 | 496.14 | 61.49 |
Earnings From Continuing Operations | 7,319 | 16,343 | 998.28 | 6,879 | 3,744 |
Minority Interest in Earnings | 161.18 | 502.28 | 291.85 | -3.95 | 195.56 |
Net Income | 7,481 | 16,845 | 1,290 | 6,875 | 3,939 |
Net Income to Common | 7,481 | 16,845 | 1,290 | 6,875 | 3,939 |
Net Income Growth | -55.59% | 1205.72% | -81.24% | 74.54% | - |
Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 |
Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 |
Shares Change (YoY) | 0.02% | 0.01% | -0.12% | -0.65% | -9.44% |
EPS (Basic) | 658.00 | 1482.00 | 113.51 | 604.21 | 343.93 |
EPS (Diluted) | 658.00 | 1482.00 | 113.51 | 604.00 | 343.93 |
EPS Growth | -55.60% | 1205.57% | -81.21% | 75.62% | - |
Free Cash Flow | 37,218 | -70,972 | -6,802 | -1,143 | -2,563 |
Free Cash Flow Per Share | 3273.71 | -6243.89 | -598.47 | -100.42 | -223.77 |
Gross Margin | 65.27% | 61.93% | 60.16% | 61.48% | 61.77% |
Operating Margin | 3.19% | 2.46% | 2.17% | 4.57% | -0.66% |
Profit Margin | 2.44% | 6.21% | 0.55% | 3.35% | 2.41% |
Free Cash Flow Margin | 12.13% | -26.18% | -2.91% | -0.56% | -1.57% |
EBITDA | 18,576 | 14,376 | 10,084 | 14,311 | 3,423 |
EBITDA Margin | 6.05% | 5.30% | 4.32% | 6.97% | 2.09% |
D&A For EBITDA | 8,778 | 7,698 | 5,023 | 4,930 | 4,507 |
EBIT | 9,798 | 6,678 | 5,061 | 9,381 | -1,084 |
EBIT Margin | 3.19% | 2.46% | 2.17% | 4.57% | -0.66% |
Effective Tax Rate | 5.15% | 19.25% | 76.61% | 6.73% | 1.62% |
Advertising Expenses | 7,338 | 11,337 | 5,543 | 5,776 | 5,482 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.